Gilead Sciences, Inc.

Craig S Pace

Nathan D Thomsen

Brian A Carr

Mini Balakrishnan

Xue Zhang

Heather Stephenson

John Corbin

Matthew Robert Schenauer

Doug Rehder

Helen Yu

Loredana Serafini

Tomas Cihlar

Derek Sloan

Manu Kanwar

Magdeleine S Hung

Manuel Baca

Derek Dean Sloan

Joshua Goldsmith

George Kukolj

Sheila B Clancy

Brian Moldt

Antibodies that bind to HIV gp120 and neutralize HIV are disclosed. Also disclosed are methods of using such antibodies alone or in combination with other therapeutic agents to treat or prevent HIV infection.

Antibodies that target HIV gp120 and methods of use

Provided are multi-specific antigen binding molecules, including bispecific antibodies, that bind to CD3 and an HIV antigen, including HIV envelope protein gp120. Also provided are methods of using such antigen binding molecules to treat or prevent HIV infection.

Multi-specific antigen binding molecules targeting HIV and methods of use

Provided are methods for identifying patient populations infected with HIV that can be targeted by antibodies that bind to HIV gp120 V3 glycan region.

Methods of identifying HIV patients sensitive to therapy with GP120 V3 glycan-directed antibodies

The present invention provides novel anti-HIV antibodies with improved therapeutic properties, related pharmaceutical compositions, and methods of use thereof.

Human immunodeficiency virus neutralizing antibodies

Multispecific antibodies (e.g., bispecific antibodies) that bind to HIV gp120 and CD3 are disclosed. Also disclosed are methods of using such antibodies to treat or prevent HIV infection.

Multispecific antibodies that target HIV GP120 and CD3

Antibodies that target HIV GP120 and methods of use

Growing community of inventors

Belmont, CA, United States of America

Craig S Pace